Bardia A, Krop IE, Kogawa T, Juric D, et al. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol 2024 Apr 23:JCO2301909. doi: 10.1200/JCO.23.01909.
PMID: 38652877